Beyond Barriers

A novel technology platform
for the delivery of therapeutics
across biological barriers

TECHNOLOGY INVESTORS
Gate2Brain

The solution

Gate2Brain
Technology

Gate2Brain (G2B) uses a novel technology platform for the delivery of therapeutics. Our platform is based on three families of peptide shuttles that improve the biopharmaceutical properties of cargoes such as small molecules, peptides, nanoparticles, proteins and antibodies in vitro and in vivo when conjugated to them.

The G2B technology platform is applicable to therapeutic areas in which biological barriers hinder the delivery and activity of drugs.

Read more

About us

Gate2Brain is a biotech company focused on the development of therapeutics that efficiently cross biological barriers such as the blood-brain barrier. We pursue our goals using a radically innovative peptide-based patented technology platform.

Read more
Link to: Technology
Technology

Gate2Brain (G2B) has a proprietary novel technology platform for the delivery of therapeutics across biological barriers.

Link to: Pipeline-Proof of Concept
Pipeline and Therapeutic Proof of Concept

G2B-002, the first therapeutic proof of concept of our technology platform, is aimed mainly at the treatment of rare pediatric solid tumors.

Link to: Investors
Investors

A strong network of investors ensures funding to achieve our goals.

Medicines beyond barriers

We go beyond physiological and disease barriers, as our portfolio of peptide shuttles cover barriers such as the blood-brain,
blood-retinal, skin and tumor barriers. We go beyond economic barriers, such as the lack of investment for the development of pediatric drugs. We go beyond societal barriers to provide medicines for everyone, everywhere.

Clinical Focus

Therapeutic
Proof of Concept

Our G2B therapeutic-peptide shuttle conjugates carry the drug cargo candidates to the target site in which the disease arises. G2B-002, our flagship product and proof of concept of the technology, offers a new therapeutic approach with improved biopharmaceutical properties and potent activity against rare pediatric cancers.

Our objective is for G2B-002 to reach Phase 1 clinical trials and thus have a high social impact focused on the unmet medical needs of oncology, pediatric and rare diseases.

G2B-002 shows potent preclinical activity for rare pediatric cancer indications such as pediatric high-grade gliomas, DIPG, Ewing sarcoma, rhabdomyosarcoma and neuroblastoma.

READ MORE
Gate2Brain

News & Media

Welcome to our news section, which provides a selection of our coverage in the media, industry, latest developments, plus videos, and more.

Meritxell Teixidó això de semblar una superwomen em patina moltDiari Ara

I couldn’t care less about looking like a “superwoman”

Meritxell Teixidó I couldn't care less about looking like a "superwoman" CEO & CO-FOUNDER OF…
Read more
THIS IS HOW A DRUG IS TOWED TO THE BRAINExpansión

THIS IS HOW A DRUG IS TOWED TO THE BRAIN

Sometimes drugs need a special push to be more effective and reach its final destination: the brain.…
Read more

Sometimes the impossible only comes later

"Sometimes the impossible only comes later" Established in 2020, Gate2Brain is a spinoff that is based…
Read more
📢 On December 13h, Gate2Brain will be participating together with Maribel Berges (AFFIRMA BIOTECH SL), Sven Dr. Mulfinger (Dana_positive maternal health), and Diana Ballart (The Smart Lollipop) in the i4kids Closing Event 2022, sharing achievements and failures of entrepreneurs in #pediatric and maternal #healthcare.i4kids

i4kids Closing Event 2022

On December 13h, Gate2Brain will be participating together with Maribel Berges (AFFIRMA BIOTECH SL), Sven…
Read more
Womenstartupawardsgate2Brain

WomenStarUpAwards

Meritxell Teixido, CEO/ CSO of Gate2Brain, won the #WomenStartupAwards in the “Inspiration category”. During…
Read more
WomenStartupAwards, in the "Inspiration" category.WomeninTechSpain

Finalist of Women Startup Awards

Gate2Brain is pleased to announce that our CEO, Meritxell Teixidó, has been nominated as a finalist…
Read more
desafio singaporeICEX

Desafía Singapore

The Desafía Singapore program is an initiative of ICEX and the Singapore Economic and Commercial Office,…
Read more
2 year anniversaryGate2Brain

Gate2Brain 2 year highlights at a glance

This year, to commemorate the 2nd anniversary of our company, we published a corporate booklet summarizing…
Read more
GORDON CONFERENCESgate2brain

Gordon Research Conferences

Gate2Brain is in Oxnard, on California’s south coast, USA, attending the 2022 Gordon Research Conferences,…
Read more
NEWS & MEDIA

1
2
Gate2Brain
1

Making therapies a reality for patients by addressing unmet medical needs.

2

Improving patients’ quality of life using a technology that provides superior drug transport efficacy.

Go Beyond Barriers & Contact Us

This contact form is deactivated because you refused to accept Google reCaptcha service which is necessary to validate any messages sent by the form.

Barcelona Scientific Park
Baldiri Reixac, 4-8, Torre I
08028 Barcelona, Spain
info@gate2brain.com

Gate2Brain
Gate2Brain
Gate2Brain
Gate2Brain
Gate2Brain
Gate2Brain

Gate2Brain is a biotech company focused on the development of therapeutics that efficiently cross biological barriers such as the blood-brain barrier. We use a radically innovative peptide-based patented technology.

Where to find us

Barcelona Scientific Park
Baldiri Reixac, 4-8, Torre I
08028 Barcelona, Spain
info@gate2brain.com

Social